Stocktoria
WEST PHARMACEUTICAL SERVICES INC WST
WEST PHARMACEUTICAL SERVICES INC (WST) earns a Piotroski F-score of 7/9 (strong financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 0.26% (safety: safe). FY2025 revenue was $3.1B at a 16.1% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.79 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-03 | Citigroup | Buy (main) |
| 2026-07-27 | Evercore ISI Group | Outperform (main) |
| 2026-07-13 | BNP Paribas | Outperform (init) |
| 2026-07-09 | Morgan Stanley | Equal-Weight (main) |
| 2026-07-06 | Evercore ISI Group | Outperform (main) |
| 2026-07-02 | Keybanc | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 7/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.31 |
| Retained earnings / assets | 1.025 |
| EBIT / assets | 0.137 |
| Equity / liabilities | 2.903 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| WST | WEST PHARMACEUTICAL SERVICES INC | 7/9 | 9.34 | 47.2 | +6.3% |
| MMED | MiniMed Group, Inc. | 3/9 | 4.28 | — | +14.3% |
| GMED | GLOBUS MEDICAL INC | 7/9 | 10.06 | 21.8 | +16.7% |
| PODD | INSULET CORP | 6/9 | 4.78 | 44.4 | +30.7% |
| ICUI | ICU MEDICAL INC/DE | 6/9 | 2.9 | — | -6.3% |
| TFX | TELEFLEX INC | 5/9 | 3.56 | — | +17.2% |
| IART | INTEGRA LIFESCIENCES HOLDINGS CORP | 5/9 | 1.17 | — | +1.5% |
About WEST PHARMACEUTICAL SERVICES INC
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging products. This segment also provides drug containment solutions in the form of vials, syringes, and cartridges; and self-injection devices; and a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment primarily serves pharmaceutical, diagnostic, and medical device companies. It sells and distributes its products through its sales force and distribution network, contract sales agents, and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
FAQ
Is WST financially healthy?
WEST PHARMACEUTICAL SERVICES INC's Piotroski F-score is 7/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does WST pay a dividend, and is it safe?
Yes. WEST PHARMACEUTICAL SERVICES INC pays a dividend yielding about 0.26% with a 12.4% payout ratio, rated “safe” for safety.
How profitable is WST?
In FY2025, WEST PHARMACEUTICAL SERVICES INC had a net margin of 16.1% and a return on equity of 15.5%.
Is WST overvalued or undervalued?
WEST PHARMACEUTICAL SERVICES INC trades at about 51.9× trailing earnings — near its 10-year norm (10-year range 34.0×–65.5×, median 47.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for WST?
The average Wall-Street price target for WEST PHARMACEUTICAL SERVICES INC is $404.73, about 14.9% above the recent price, from 15 analysts (consensus: strong buy).
Is WST a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on WEST PHARMACEUTICAL SERVICES INC: a Piotroski F-score of 7/9, an Altman Z″ in the safe zone, a P/E of about 47.2×, a dividend yield of 0.26%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.